Results 11 to 20 of about 676,789 (144)
Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy [PDF]
Journal of Immunotherapy and Precision Oncology, 2022 Introduction: Many studies have focused on the role of programmed death receptor ligand 1 (PD-L1) expression in predicting immunotherapy outcomes. Limited clinical data are available regarding the role of programmed death receptor 1 (PD-1; the PD-L1 ...
Nicholas J. Bevins +5 more
doaj +1 more source
Frontiers in Immunology, 2022 Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is an Epstein–Barr virus (EBV)-related, rare subtype of non-small-cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICI) show durable responses in advanced NSCLC. However, their effects and
Yu-Min Zhong +34 more
doaj +1 more source
USE OF NEAR INFRARED TECHNOLOGY TO PREDICT FATTY ACID GROUPS IN COMMERCIAL GROUND MEAT PRODUCTS [PDF]
Poljoprivreda, 2015 Near infrared transmittance (NIT, 850 to 1048 nm) spectroscopy was used to predict groups of fatty acids (FA), namely saturated FA (SFA), monounsaturated FA (MUFA) and polyunsaturated FA (PUFA), in commercial ground meat samples aiming to develope a fast
Sofia Ton +5 more
doaj +1 more source
Frontiers in Immunology, 2021 Immune checkpoint inhibitors, such as monoclonal antibodies targeting programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1), have achieved enormous success in the treatment of several cancers.
Yuanyuan Wang +19 more
doaj +1 more source
PD-1 and PD-1 ligands: from discovery to clinical application [PDF]
International Immunology, 2007 Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2.
Taku, Okazaki, Tasuku, Honjo
openaire +2 more sources
Italian Journal of Medicine, 2014 A 59-year old woman was admitted for fatigue and arm paresthesias with Trousseau sign. Her medical history included thyroidectomy and hypercholesterolemia recently treated with simvastatin.
Anna Piva +2 more
doaj +1 more source
PD-1, gender, and autoimmunity [PDF]
Autoimmunity Reviews, 2010 Programmed death 1 (PD-1) and its ligands (PD-L1 and PD-L2) are responsible for inhibitory T cell signaling that helps mediate the mechanisms of tolerance and immune homeostasis. The PD-1:PD-L signaling pathway has been shown to play an important role in a variety of diseases, including autoimmune conditions, chronic infection, and cancer.
Ravi K, Dinesh +2 more
openaire +2 more sources
EMBO Molecular Medicine, 2020 Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8+ cytotoxic T lymphocyte (CTL ...
Zhenzhen Fan +15 more
doaj +1 more source
Journal of Hematology & Oncology, 2021 CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL).
Chunmeng Wang +10 more
doaj +1 more source
Molecules, 2021 Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction is currently the focus in the field of cancer immunotherapy, and so far, several monoclonal antibodies (mAbs) have achieved encouraging outcomes in cancer ...
Hongbo Zhang +9 more
doaj +1 more source